In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on La Jolla Pharma (NASDAQ: LJPC), with a price target of $83. The company’s shares closed yesterday at $31.16.
White noted:
“Exchange NASDAQ Value (M) 660.6 Market Cap (M) $815 Public Market Float (M) 6.0 Shares Outstanding (M) 26.2 3 Interest (M) 7.32 Cash (M) $154.4 Total Debt (M) $0.0 Quarterly EPS may not sum to total due to rounding or change in share count.”
According to TipRanks.com, White is a 5-star analyst with an average return of 24.6% and a 50.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Mirati Therapeutics.
La Jolla Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $54.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.36 and a one-year low of $22.68. Currently, La Jolla Pharma has an average volume of 544.2K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LJPC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
La Jolla Pharmaceutical Co. is a biopharmaceutical company, which engages in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
